What is the main business of Sanford Biotech?

The main business activity of Sanford Biotech focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on July 20, 2017.

Where is the headquarters located?

The headquarters is located at: Aleja Marsz. Józefa Piłsudskiego 35, 05-077 Warszawa.

Who is on the management board?

The management board consists of: Joanna Sanford (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 7,700 (approx. $2,080).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of $2,065, representing a decrease of 7.1% compared to 2023.

Is the company profitable?

No, the company recorded a net loss of $9,153 in 2024. For comparison, in 2023 the loss was $2,579, meaning the company increased its loss by 237.1%.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $832 in 2024, representing 100% of all operating expenses.

Sanford Biotechsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2017-07-20

Share capital

7 700,00 PLN

Activity description

Sanford Biotech is a company that develops stem cell therapies and growth factor treatments for both human and veterinary medicine. It offers advanced biological therapies for companion animals, including innovative treatments for arthritis in dogs and atopic dermatitis in dogs and cats. Additionally, it focuses on therapies for horses and dairy cattle, reflecting a shift in how these animals are perceived and treated in veterinary care.

Registered address

Aleja Marsz. Józefa Piłsudskiego 35/E, 05-077 Warszawa, Poland

Website

sanfordbiotech.com

Phone

Electronic delivery address

AE:PL-49467-72267-BWUFF-18

Financials

Revenue history

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 2.59kMedianUSD 816.16kAverageUSD 29.28m

Net profit

This companyUSD -15.16kMedianUSD 8.96kAverageUSD 2.64m

Operating costs

This companyUSD 13.80kMedianUSD 701.47kAverageUSD 19.26m

Assets

This companyUSD 112.13kMedianUSD 800.13kAverageUSD 29.34m

Industry

Bank accounts

Registered as a VAT taxpayer on 2025-08-01. Active

ING Bank Śląski
54 1050 1025 1000 0090 8021 6162

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Authorized Representatives

Joanna Sanford — Management Board Member

Manner of representation

In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Milton Essex S.A.	154	$2,079.96	100%

Beneficial owners

Person	Rights
Joanna Sanford (59)	Shareholder of a limited liability company, 4900.0 PLN

Competitors

	Name	Revenue	Website
	Bioresearch PharmaS.A.	$21,432.15	bioresearchpharma.com

Change history

Date	Event
2025-09-17	Share capital change (5,000.00 PLN → 7,700.00 PLN)
2025-09-17	PKD change (Removed: 86.90.E; Added: 21.20.Z, 32.50.B, 46.46.Z, 47.73.Z, 47.74.Z, 72.10.Z, 75.00, 86.91.B, 86.99.D)
2017-07-20	Entered in the register

FAQ

Last updated: 2026-07-17